Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)

Glynne‐Jones, Robert; Sebag‐Montefiore, D.; Samuel, Leslie; Falk, S.; Maughan, T; McDonald, A.F.

doi:10.1200/jco.2005.23.16_suppl.3527

Cited by 19 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Glynne-Jones et al (2005) reported on a phase II trial assessing the addition of two doses of oxaliplatin 130 mg/m 2 , 4 weeks apart, during pelvic RT (45 Gy in 5 weeks) associated with a continuous assumption of capecitabine (650 mg/m 2 twice daily), followed by surgery. Ninety-five patients were treated, and 85 underwent surgery: a pCR was achieved in 16 (19%) patients, and a Tmic was found at the pathologic examination in additional 21 (25%) patients.…”

Section: Capecitabine In the Primary Management Of Rectal Cancermentioning

confidence: 99%

Role of oxaliplatin in the treatment of colorectal cancer

Comella

Casaretti

Sandomenico

et al. 2009

TCRM

View full text Add to dashboard Cite

Abstract:Oxaliplatin is a third-generation platinum compound that has shown a defi nite role in the management of colorectal cancer (CRC). Oxaliplatin in combination with fl uorouracil and leucovorin in the FOLFOX4 regimen represents a new standard of treatment in the adjuvant setting as well as for the metastatic disease. The combination of oxaliplatin with capecitabine in the XELOX regimen has been demonstrated to be not inferior to FOLFOX4 in metastatic patients, and it is under evaluation, with or without bevacizumab, in the post-surgical management of resected patients. FOLFOX4 and XELOX regimens represent a backbone on which to add new targeted drugs. Indeed, the combination of bevacizumab with either FOLFOX4 or XELOX signifi cantly prolonged the progression-free survival and overall survival in comparison with FOLFOX4 or XELOX combined with placebo in metastatic CRC patients, while FOLFOX4 plus cetuximab produced a signifi cantly greater activity than FOLFOX4 alone in metastatic CRC patients with K-RAS wild type.

show abstract

Section: Capecitabine In the Primary Management Of Rectal Cancermentioning

confidence: 99%

Role of oxaliplatin in the treatment of colorectal cancer

Comella

Casaretti

Sandomenico

et al. 2009

TCRM

View full text Add to dashboard Cite

show abstract

“…Central to the course was the opportunity to observe live TME surgery with two-way discussion between operating and lecture theatres using video conferencing facilities. There were also seminars on the latest advances in imaging[ 6 , 7 ], pathology[ 8 , 9 ], pre-operative radio and chemo-radiotherapy[ 10 ], supportive care issues including stoma management, and the management of secondary disease. One session was dedicated to the challenges of multidisciplinary team working.…”

Section: Methodsmentioning

confidence: 99%

A pre-post test evaluation of the impact of the PELICAN MDT-TME Development Programme on the working lives of colorectal cancer team members

Taylor

Sippitt

Collins

et al. 2010

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundThe PELICAN Multidisciplinary Team Total Mesorectal Excision (MDT-TME) Development Programme aimed to improve clinical outcomes for rectal cancer by educating colorectal cancer teams in precision surgery and related aspects of multidisciplinary care. The Programme reached almost all colorectal cancer teams across England. We took the opportunity to assess the impact of participating in this novel team-based Development Programme on the working lives of colorectal cancer team members.MethodsThe impact of participating in the programme on team members' self-reported job stress, job satisfaction and team performance was assessed in a pre-post course study. 333/568 (59%) team members, from the 75 multidisciplinary teams who attended the final year of the Programme, completed questionnaires pre-course, and 6-8 weeks post-course.ResultsAcross all team members, the main sources of job satisfaction related to working in multidisciplinary teams; whilst feeling overloaded was the main source of job stress. Surgeons and clinical nurse specialists reported higher levels of job satisfaction than team members who do not provide direct patient care, whilst MDT coordinators reported the lowest levels of job satisfaction and job stress. Both job stress and satisfaction decreased after participating in the Programme for all team members. There was a small improvement in team performance.ConclusionsParticipation in the Development Programme had a mixed impact on the working lives of team members in the immediate aftermath of attending. The decrease in team members' job stress may reflect the improved knowledge and skills conferred by the Programme. The decrease in job satisfaction may be the consequence of being unable to apply these skills immediately in clinical practice because of a lack of required infrastructure and/or equipment. In addition, whilst the Programme raised awareness of the challenges of teamworking, a greater focus on tackling these issues may have improved working lives further.

show abstract

“…Several phase I/II trials have examined oxaliplatin plus a fluoropyrimidine as radiation sensitizers in rectal cancer CRT [89–101] (Table 2). Response rates in terms of pCR appear to be increased compared with historical reports using a single agent fluoropyrimidine.…”

Section: Increasing the Potency Of Chemoradiation Regimes: Potential mentioning

confidence: 99%

Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer

Gollins

2010

Colorectal Disease

View full text Add to dashboard Cite

show abstract

Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)

Cited by 19 publications

References 0 publications

Role of oxaliplatin in the treatment of colorectal cancer

Role of oxaliplatin in the treatment of colorectal cancer

A pre-post test evaluation of the impact of the PELICAN MDT-TME Development Programme on the working lives of colorectal cancer team members

Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer

Contact Info

Product

Resources

About